Cargando…

Relapse-independent multiple sclerosis progression under natalizumab

The objective of this study was to investigate confirmed progression independent of relapse activity in relapsing-remitting multiple sclerosis patients under long-term natalizumab treatment. We performed a retrospective, cross-sectional study of clinical data captured between 1994 and 2019 at two Ge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Graf, Jonas, Leussink, Verena I, Soncin, Giulia, Lepka, Klaudia, Meinl, Ingrid, Kümpfel, Tania, Meuth, Sven G, Hartung, Hans-Peter, Havla, Joachim, Aktas, Orhan, Albrecht, Philipp
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8573181/ https://www.ncbi.nlm.nih.gov/pubmed/34755108 http://dx.doi.org/10.1093/braincomms/fcab229

Ejemplares similares

Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of Plasmablasts
por: Schlüter, Miriam, et al.
Publicado: (2021)

Bridging, switching or drug holidays – how to treat a patient who stops natalizumab?
por: Havla, Joachim, et al.
Publicado: (2013)

Association of Retinal Layer Thickness With Cognition in Patients With Multiple Sclerosis
por: Baetge, Sharon Jean, et al.
Publicado: (2021)

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy
por: Graf, Jonas, et al.
Publicado: (2017)

Redox Events As Modulators of Pathology and Therapy of Neuroinflammatory Diseases
por: Lepka, Klaudia, et al.
Publicado: (2016)

Neurological phenotypes in patients with NLRP3-, MEFV-, and TNFRSF1A low-penetrance variants
por: Mulazzani, Elisabeth, et al.
Publicado: (2020)

Multiple Sclerosis: Switching from Natalizumab to Other High-Efficacy Treatments to Mitigate Progressive Multifocal Leukoencephalopathy Risk
por: Hartung, Hans-Peter, et al.
Publicado: (2021)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Natalizumab restores aberrant miRNA expression profile in multiple sclerosis and reveals a critical role for miR-20b
por: Ingwersen, Jens, et al.
Publicado: (2015)

Alemtuzumab: A new therapy for active relapsing–remitting multiple sclerosis
por: Hartung, Hans-Peter, et al.
Publicado: (2015)

Thinking outside the box: non-canonical targets in multiple sclerosis
por: Bierhansl, Laura, et al.
Publicado: (2022)

First manifestation of multiple sclerosis after immunization with the Pfizer-BioNTech COVID-19 vaccine
por: Havla, Joachim, et al.
Publicado: (2021)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
por: Metz, Imke, et al.
Publicado: (2011)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

A randomized study of natalizumab dosing regimens for relapsing–remitting multiple sclerosis
por: Trojano, Maria, et al.
Publicado: (2021)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Use of Natalizumab in Patients with Active Relapsing-Remitting Multiple Sclerosis in Kuwait
por: Alroughani, R., et al.
Publicado: (2013)

Practical Clinical Guidelines for Natalizumab Treatment in Patients With Relapsing Multiple Sclerosis
por: O'Leary, Shirley, et al.
Publicado: (2023)

Erratum zu: Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Ocrelizumab zur Behandlung der Multiplen Sklerose
por: Graf, Jonas, et al.
Publicado: (2020)

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Inner Retinal Layer Changes Reflect Changes in Ambulation Score in Patients with Primary Progressive Multiple Sclerosis
por: Gernert, Jonathan A., et al.
Publicado: (2023)

Therapy challenges for NMOSD in a patient with HIV
por: Engels, Daniel, et al.
Publicado: (2023)

Real-world evidence of ocrelizumab-treated relapsing multiple sclerosis cohort shows changes in progression independent of relapse activity mirroring phase 3 trials
por: Ingwersen, J., et al.
Publicado: (2023)

Ocrelizumab Treatment Modulates B-Cell Regulating Factors in Multiple Sclerosis
por: Ho, Samantha, et al.
Publicado: (2023)

Neurological manifestations in autoinflammatory syndromes: a series of 131 patients from our neuroimmunology departement
por: Schuh, E, et al.
Publicado: (2015)

Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS
por: Gahlen, Anna, et al.
Publicado: (2017)

Treatment with Natalizumab in Relapsing–Remitting Multiple Sclerosis Patients Induces Changes in Inflammatory Mechanism
por: Ramos-Cejudo, Jaime, et al.
Publicado: (2011)

Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: a case report
por: Gatzonis, Stylianos, et al.
Publicado: (2009)

Impact of Natalizumab on Ambulatory Improvement in Secondary Progressive and Disabled Relapsing-Remitting Multiple Sclerosis
por: Cadavid, Diego, et al.
Publicado: (2013)

Impact of Natalizumab Treatment on Fatigue, Mood, and Aspects of Cognition in Relapsing–Remitting Multiple Sclerosis
por: Kunkel, Annett, et al.
Publicado: (2015)

Extended Interval Dosing Natalizumab and impact on neuropsychological deficits in Relapsing-Remitting Multiple Sclerosis
por: McManus, Eileen J., et al.
Publicado: (2022)

Cost-effectiveness analysis of rituximab versus natalizumab in patients with relapsing remitting multiple sclerosis
por: Rezaee, Mehdi, et al.
Publicado: (2022)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Real-world effectiveness of natalizumab treatment in patients with relapsing multiple sclerosis in Argentina and Chile
por: Ysrraelit, Maria Celica, et al.
Publicado: (2021)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_f5q02hamduesro1i36j63qnto0